eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases

Propionic Acidemia (Propionyl CoA Carboxylase Deficiency): Treatment & Medication

Author: Karl S Roth, MD, Professor and Chair, Department of Pediatrics, Creighton University School of Medicine
Contributor Information and Disclosures

Updated: Sep 10, 2009

Treatment

Medical Care

  • Most patients with propionyl coenzyme A (CoA) carboxylase deficiency (propionic acidemia) are so ill at presentation that they have already been admitted to a hospital, which should facilitate appropriate diagnosis and early treatment.
  • Because the usual major metabolic precursors of propionic acid are the essential amino acids (isoleucine, valine, threonine, methionine), halt all protein ingestion and emphasize alternative sources of calories on a temporary basis.
  • Ketoacidosis is best treated with increased carbohydrate calories, bicarbonate replacement, and increased fluids to enhance excretion. In severely ill patients, metabolic reversal can be expedited by an insulin drip, but this should only be administered in an intensive care setting.
  • Reinitiate protein feeding to a level of protein no greater than 1.5 g/kg/d after the patient's condition has normalized. From this point, the patient should be under the care of a biochemical geneticist who may prescribe a special diet prior to discharge.

Consultations

  • Biochemical geneticist
  • Nutritionist

Diet

  • Appropriate dietary management is the mainstay of treatment.
  • Several commercially produced formulas are available that provide a protein supplement without any of the 4 amino acids that result in propionate production. However, because they are all essential in humans, closely monitored quantities of isoleucine, valine, threonine, and methionine must be added. For this reason, collaboration between the biochemical geneticist and the nutritionist is imperative.

Activity

  • No restriction is necessary.

Medication

  • Some authorities recommend oral biotin supplements in pharmacological dosage (10 mg/d) for propionyl coenzyme A (CoA) carboxylase deficiency (ie, propionic acidemia). Although no complication of biotin administration is known, even in such large doses, no good clinical evidence suggests that such treatment is effective.
  • Some authorities also advocate carnitine supplementation. Although such treatment makes sense biochemically, little evidence suggests any efficacy.

More on Propionic Acidemia (Propionyl CoA Carboxylase Deficiency)

Overview: Propionic Acidemia (Propionyl CoA Carboxylase Deficiency)
Differential Diagnoses & Workup: Propionic Acidemia (Propionyl CoA Carboxylase Deficiency)
Treatment & Medication: Propionic Acidemia (Propionyl CoA Carboxylase Deficiency)
Follow-up: Propionic Acidemia (Propionyl CoA Carboxylase Deficiency)
Multimedia: Propionic Acidemia (Propionyl CoA Carboxylase Deficiency)
References
[ CLOSE WINDOW ]

References

  1. Hsia YE, Scully KJ, Rosenberg LE. Defective propionate carboxylation in ketotic hyperglycinaemia. Lancet. Apr 12 1969;1(7598):757-8. [Medline].

  2. Morrow G 3rd, Barness LA, Auerbach VH, et al. Observations on the coexistence of methylmalonic acidemia and glycinemia. J Pediatr. May 1969;74(5):680-90. [Medline].

  3. Hsia YE, Scully KJ, Rosenberg LE. Inherited propionyl-Coa carboxylase deficiency in "ketotic hyperglycinemia.". J Clin Invest. Jan 1971;50(1):127-30. [Medline]. [Full Text].

  4. Bruggink JL, van Spronsen FJ, Wijnberg-Williams BJ, Bos AF. Pilot use of the early motor repertoire in infants with inborn errors of metabolism: outcomes in early and middle childhood. Early Hum Dev. Jul 2009;85(7):461-5. [Medline].

  5. [Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. Sep 2004;114(3):889-94. [Medline].

  6. Baumgartner D, Scholl-Burgi S, Sass JO, et al. Prolonged QTc intervals and decreased left ventricular contractility in patients with propionic acidemia. J Pediatr. Feb 2007;150(2):192-7. [Medline].

  7. Feliz B, Witt DR, Harris BT. Propionic acidemia: a neuropathology case report and review of prior cases. Arch Pathol Lab Med. Aug 2003;127(8):e325-8. [Medline].

  8. Filipowicz HR, Ernst SL, Ashurst CL, Pasquali M, Longo N. Metabolic changes associated with hyperammonemia in patients with propionic acidemia. Mol Genet Metab. Jun 2006;88(2):123-30. [Medline].

  9. Gravel RA, Lam KF, Scully KJ, Hsia Y. Genetic complementation of propionyl-CoA carboxylase deficiency in cultured human fibroblasts. Am J Hum Genet. Jul 1977;29(4):378-88. [Medline].

  10. Ianchulev T, Kolin T, Moseley K, Sadun A. Optic nerve atrophy in propionic acidemia. Ophthalmology. Sep 2003;110(9):1850-4. [Medline].

  11. Lamhonwah AM, Gravel RA. Propionicacidemia: absence of alpha-chain mRNA in fibroblasts from patients of the pccA complementation group. Am J Hum Genet. Dec 1987;41(6):1124-31. [Medline].

  12. Meyburg J, Hoffmann GF. Liver transplantation for inborn errors of metabolism. Transplantation. Sep 27 2005;80(1 Suppl):S135-7. [Medline].

  13. Nyhan WL, Bordern M, Childs B. Idiopathic hyperglycinemia: a new disorder of amino acid metabolism. II. The concentrations of other amino acids in the plasma and their modification by the administration of leucine. Pediatrics. Apr 1961;27:539-50. [Medline].

  14. Perez-Cerda C, Perez B, Merinero B, et al. Prenatal diagnosis of propionic acidemia. Prenat Diagn. Dec 15 2004;24(12):962-4. [Medline].

  15. Saunders M, Sweetman L, Robinson B, et al. Biotin-response organic aciduria. Multiple carboxylase defects and complementation studies with propionic acidemia in cultured fibroblasts. J Clin Invest. Dec 1979;64(6):1695-702. [Medline]. [Full Text].

  16. Wolf B, Willard HF, Rosenberg LE. Kinetic analysis genetic complementation in heterokaryons of propionyl CoA carboxylase-deficient human fibroblasts. Am J Hum Genet. 1980;32(1):16-25. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

propionic acidemia, ketotic hyperglycinemia, propionyl coenzyme A carboxylase deficiency, propionate carboxylation defect, multiple carboxylase deficiency, propionyl-CoA carboxylase deficiency, severe ketoacidosis, protein ingestion, hyperammonemia, pancytopenia, acidosis, mental retardation, pancytopenia, failure to thrive, feeding intolerance, anorexia

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Karl S Roth, MD, Professor and Chair, Department of Pediatrics, Creighton University School of Medicine
Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Clinical Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, Society for Pediatric Research, and Southern Society for Pediatric Research
Disclosure: MDS Pharma Salary Employment

Medical Editor

Erawati V Bawle, MD, FAAP, FACMG, Division of Genetic and Metabolic Disorders, Children's Hospital of Michigan; Professor (Clinician-Educator), Department of Pediatrics, Wayne State University School of Medicine
Erawati V Bawle, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, American Medical Association, and American Society of Human Genetics
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Robert Anthony Saul, MD, Clinical Professor, Department of Pediatrics, University of South Carolina; Senior Clinical Geneticist, Greenwood Genetic Center
Robert Anthony Saul, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, and American College of Physician Executives
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting

Chief Editor

Bruce Buehler, MD, Professor of Genetics, Munroe Meyer Institute, Professor, Department of Pediatrics, Pathology and Microbiology, University of Nebraska Medical Center
Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.